The Universally Accessible Cheaper and Quality Medicines Act of 2008 has succeeded in bringing down the cost of essential drugs and those to treat chronic diseases in The Philippines.
The coming into force on July 4, 2008 of Republic Act No. 9502, known as the Universally Accessible Cheaper and Quality Medicines Act of 2008, has succeeded in bringing down the cost of essential drugs and those to treat chronic diseases.
On the other hand, because of the desire of the courts to help the poor gain access to cheaper medicine, it also resulted in incorrect jurisprudence. The decision of the Supreme Court in the case of Roma Drug v GlaxoSmithKline which was promulgated on April 16, 2009 neglected to consider the more important objective of the law to ensure that the quality of medicine is not compromised.
Roma Drug imported Augmentin, Orbenin, Amoxil and Ampiclox, which it sold without obtaining prior registration from the Bureau of Food and Drugs (BFAD), now the Food and Drug Administration (FDA). The BFAD registrations of these drugs were made by GlaxoSmithKline.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email tech support.